

Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR T-cell platforms

Authors: Carmine Deluca, Michael Beyer, Jennifer M. Ahlstrom, Robert Z. Orłowski, Beth Faiman, Irene M. Ghobrial, Abigail Brugger, Heather Drew.
Organizations: PVI, PeerView Institute for Medical Education, New York, NY; HealthTree Foundation, Lehi, UT; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA.





BACKGROUND

The management of **multiple myeloma (MM)** continues to be transformed by the use of **CD38 antibodies and B-cell maturation antigen (BCMA) immunotherapy (chimeric antigen receptor (CAR-T) and bispecific antibodies)** in newly diagnosed and relapsed/refractory MM (NDMM and RRMM), respectively.

However, real-world evidence shows that **these approaches are under-utilized** across lines of therapy and that educational outreach to patients on their use is inadequate (Puig N et al. ASH 2022. Abstract 1859; Pink S et al. ISPOR 2022. Abstract HSD44; Terpos E et al. Blood Cancer J. 2021;11:40; Adu Y et al. ASH 2023. Abstract 2418).


METHODOLOGY

PeerView partnered with HealthTree Foundation for Multiple Myeloma to develop **4 live events and 5 online enduring activities** from June 2022 to June 2023.


-  These educational initiatives aimed to educate clinicians on integrating CD38 and BCMA antibody platforms into patient care.
-  **Objectives included improving knowledge and skills** for using these therapies in multiple myeloma treatment sequences.
-  The initiatives featured **patient perspectives, tools and resources** to foster clinician-patient communication on antibody and CAR-T therapy.
-  Pre- and post-activity assessments measured **knowledge and skill improvements**, comparing participants' responses with a matched sample of nonparticipants in a meta-analysis across all 9 activities.

RESULTS

Total Participants: **12,248 Learners**



In all activities, learners' **knowledge and skills improved**, with increases of:



CONCLUSION

Improvements in knowledge and skills, combined with a greater focus on patient-centricity, suggest that learners are poised to more effectively integrate CD38 antibodies and BCMA immunotherapy into guideline-recommended MM care that improves the overall well-being and outcomes of patients with MM.

